Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anticoagulant Reversal”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Early research (Phase 1)Study completedNCT01826266
What this trial is testing

Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

Who this might be right for
Anticoagulant ReversalReversal of Edoxaban Induced Anticoagulation
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. 83
Large-scale testing (Phase 3)Study completedNCT00168077
What this trial is testing

Prothrombin Complex Concentrate for Anticoagulant Reversal

Who this might be right for
Acquired Coagulation Factor Deficiency
CSL Behring 40
Not applicableWithdrawnNCT03537521
What this trial is testing

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots

Who this might be right for
Severe BleedingUrgent Surgery
Cardioangiologisches Centrum Bethanien
Post-approval studies (Phase 4)UnknownNCT03473132
What this trial is testing

Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)

Who this might be right for
AnticoagulationAnticoagulation Reversal
Brigham and Women's Hospital 50
Large-scale testing (Phase 3)Study completedNCT00708435
What this trial is testing

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Who this might be right for
Blood Coagulation DisordersAcute Major Bleeding
CSL Behring 216
Large-scale testing (Phase 3)Study completedNCT00618098
What this trial is testing

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

Who this might be right for
Reversal of Anticoagulant Treatment
Octapharma 200
Post-approval studies (Phase 4)Study completedNCT01343381
What this trial is testing

Comparison of Heparin Types; Efficacy and Safety

Who this might be right for
Coronary Artery Disease
McMaster University 21
Not applicableStudy completedNCT01722786
What this trial is testing

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists

Who this might be right for
Severe BleedingUrgent Surgery
Cardioangiologisches Centrum Bethanien 272
Post-approval studies (Phase 4)Study completedNCT01159210
What this trial is testing

Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal

Who this might be right for
Prothrombin Complex Factor Deficiency
Baxalta now part of Shire 61
Not applicableStudy completedNCT03254147
What this trial is testing

Medical Need of OAC Reversal

Who this might be right for
Atrial Fibrillation
Boehringer Ingelheim 53,969
Large-scale testing (Phase 3)Study completedNCT02329327
What this trial is testing

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

Who this might be right for
Bleeding
Alexion Pharmaceuticals, Inc. 479
Large-scale testing (Phase 3)Study completedNCT02104947
What this trial is testing

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Who this might be right for
Hemorrhage
Boehringer Ingelheim 503
Early research (Phase 1)Ended earlyNCT00770718
What this trial is testing

Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage

Who this might be right for
Intracranial Hemorrhage
University of Utah 2
Early research (Phase 1)Looking for participantsNCT07024160
What this trial is testing

Phase I Study of MT1011 Injection in Healthy Subjects

Who this might be right for
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Shaanxi Micot Pharmaceutical Technology Co., Ltd. 40
Early research (Phase 1)Study completedNCT04543383
What this trial is testing

Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

Who this might be right for
Healthy
Janssen Research & Development, LLC 52
Early research (Phase 1)Study completedNCT01955720
What this trial is testing

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Who this might be right for
Hemorrhage
Boehringer Ingelheim 46
Testing effectiveness (Phase 2)Study completedNCT02206087
What this trial is testing

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

Who this might be right for
Healthy
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. 60
Large-scale testing (Phase 3)Study completedNCT02815670
What this trial is testing

Reversal Dabigatran Anticoagulant Effect With Idarucizumab

Who this might be right for
Hemorrhage
Boehringer Ingelheim 1
Large-scale testing (Phase 3)Study completedNCT02740335
What this trial is testing

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Who this might be right for
Significant Bleeding Risk
Octapharma 208
Large-scale testing (Phase 3)Study completedNCT02831660
What this trial is testing

CU Programme of Idarucizumab for Japanese Patients

Who this might be right for
Hemorrhage
Boehringer Ingelheim 1
Next Page